{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:27:45Z","timestamp":1790036865797,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00277-010-0945-x","type":"journal-article","created":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T12:28:01Z","timestamp":1269865681000},"page":"889-896","source":"Crossref","is-referenced-by-count":29,"title":["Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"89","author":[{"given":"Anastasios","family":"Chatzitolios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Venizelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Tripsiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Anastassopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"945_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/978-3-642-18653-0_6","volume-title":"Histopathology of nodal and extranodal non-Hodgkin\u2019s lymphomas. 3rd, completely rev. and updated ed","author":"AC Feller","year":"2004","unstructured":"Feller AC, Diebold J (2004) Histopathology of nodal and extranodal non-Hodgkin\u2019s lymphomas. 3rd, completely rev. and updated ed. Springer, Berlin, p 186"},{"key":"945_CR2","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/sj.leu.2401954","volume":"14","author":"M Irisarri","year":"2000","unstructured":"Irisarri M, Plumas J, Bonnefoix T et al (2000) Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin\u2019s lymphoma B cell line. Leukemia 14:2149\u20132158","journal-title":"Leukemia"},{"key":"945_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-0028-1086028","volume":"220","author":"A Troeger","year":"2008","unstructured":"Troeger A, Glouchkova L, Escherich G et al (2008) Reduced expression of defective modulation of TNF receptor\/ligand family molecules on proB-ALL blasts. Klin Pediatr 220:353\u2013357","journal-title":"Klin Pediatr"},{"key":"945_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1074-7613(00)80305-2","volume":"5","author":"TS Griffith","year":"1996","unstructured":"Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune-privileged cite induces immunological tolerance. Immunity 5:7\u201316","journal-title":"Immunity"},{"key":"945_CR5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/10428190109097702","volume":"42","author":"TH Landowski","year":"2001","unstructured":"Landowski TH, Moscinski L, Burke R (2001) CD95 antigen mutations in hematopoietic malignancies (review). Leuk Lymphoma 42:835\u2013846","journal-title":"Leuk Lymphoma"},{"key":"945_CR6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V89.2.601","volume":"89","author":"WH Wilson","year":"1997","unstructured":"Wilson WH, Teruya-Feldstein J, Fest T (1997) Relationship of P53, BCL2, and tumor proliferation to clinical drug resistance in non-Hodgkin\u2019s lymphomas. Blood 89:601\u2013609","journal-title":"Blood"},{"key":"945_CR7","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","volume":"24","author":"SL Harris","year":"2005","unstructured":"Harris SL, Levine AJ (2005) The P53 pathway: positive and negative feedback loops (review). Oncogene 24:2899\u20132908","journal-title":"Oncogene"},{"key":"945_CR8","first-page":"197","volume":"3","author":"RJ Steele","year":"2005","unstructured":"Steele RJ, Lane DP (2005) P53 in cancer: a paradigm for modern management of cancer (review). Surg 3:197\u2013205","journal-title":"Surg"},{"key":"945_CR9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm0697-614","volume":"3","author":"G Kroemer","year":"1997","unstructured":"Kroemer G (1997) The proto-oncogene BCL2 and its role in regulating apoptosis. Nat Med 3:614\u2013620","journal-title":"Nat Med"},{"key":"945_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","volume":"16","author":"DT Chao","year":"1998","unstructured":"Chao DT, Korsmeyer SJ (1998) BCL-2 family: regulators of cell death. Annu Rev Immunol 16:395\u2013419","journal-title":"Annu Rev Immunol"},{"key":"945_CR11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1056\/NEJM199309023291003","volume":"329","author":"F Pazella","year":"1993","unstructured":"Pazella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB et al (1993) BCL2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690\u2013694","journal-title":"N Engl J Med"},{"key":"945_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2559.1995.tb00628.x","volume":"26","author":"F Pazella","year":"1995","unstructured":"Pazella F, Gatter K (1995) What is the value of BCL2 protein detection for histopathologists? Histopathology 26:89\u201393","journal-title":"Histopathology"},{"key":"945_CR13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0002-9440(10)63195-1","volume":"164","author":"S Wohlfart","year":"2004","unstructured":"Wohlfart S, Sebinger D, Gruber P (2004) FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphomas DLBCL. Am J Pathol 164:1081\u20131089","journal-title":"Am J Pathol"},{"key":"945_CR14","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood.V84.8.2412.2412","volume":"84","author":"J Imamura","year":"1994","unstructured":"Imamura J, Miyoshi I, Koeffler HP (1994) P53 in hematologic malignancies. Blood 84:2412\u20132421","journal-title":"Blood"},{"key":"945_CR15","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","volume":"87","author":"L Hernandez","year":"1996","unstructured":"Hernandez L, Fest T, Cazorla M et al (1996) P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351\u20133359","journal-title":"Blood"},{"key":"945_CR16","first-page":"1527","volume":"63","author":"Y Li","year":"2003","unstructured":"Li Y, Raffo AJ, Drew L, Mao Y (2003) FAS-mediated apoptosis is dependent on wild-type P53 status in human cancer cells expressing a temperature-sensitive P53 mutant alanine-143. Cancer Res 63:1527\u20131533","journal-title":"Cancer Res"},{"key":"945_CR17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3835(01)00404-9","volume":"165","author":"GC Das","year":"2001","unstructured":"Das GC, Holiday D, Gallardo R, Haas C (2001) Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type P53 status and under isogenic condition. Cancer Lett 165:147\u2013153","journal-title":"Cancer Lett"},{"key":"945_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.onc.1204060","volume":"20","author":"ZA Stewart","year":"2001","unstructured":"Stewart ZA, Tang LJ, Pietenpol JA (2001) Increased P53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20:113\u2013124","journal-title":"Oncogene"},{"key":"945_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s004419900160","volume":"301","author":"G Makin","year":"2000","unstructured":"Makin G, Hickman JA (2000) Apoptosis and cancer chemotherapy. Cell Tissue Res 301:143\u2013152","journal-title":"Cell Tissue Res"},{"key":"945_CR20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bjc.1994.61","volume":"69","author":"MA Piris","year":"1994","unstructured":"Piris MA, Pezella F, Martinez-Montero JC et al (1994) P53 and BCL2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337\u2013341","journal-title":"Br J Cancer"},{"key":"945_CR21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00001622-199511000-00012","volume":"7","author":"JC Reed","year":"1995","unstructured":"Reed JC (1995) Regulation of apoptosis by BCL2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541\u2013546","journal-title":"Curr Opin Oncol"},{"key":"945_CR22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V87.1.265.265","volume":"87","author":"O Hermine","year":"1996","unstructured":"Hermine O, Haioun C, Lepage E (1996) Prognostic significance of BCL2 protein expression in aggressive non-Hodgkin\u2019s lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Blood 87:265\u2013272","journal-title":"Blood"},{"key":"945_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V81.1.151.151","volume":"81","author":"T Miyashita","year":"1993","unstructured":"Miyashita T, Reed JC (1993) BCL2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 81:151\u2013157","journal-title":"Blood"},{"key":"945_CR24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.V84.4.1201.1201","volume":"84","author":"K Iwai","year":"1994","unstructured":"Iwai K, Miyawaki T, Takizawa T (1994) Differential expression of BCL2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84:1201\u20131208","journal-title":"Blood"},{"key":"945_CR25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood.V83.7.1856.1856","volume":"83","author":"T Yoshino","year":"1994","unstructured":"Yoshino T, Kondo E, Cao L (1994) Inverse expression of BCL2 protein and FAS antigen in lympho-blasts in peripheral blood T and B lymphocytes. Blood 83:1856\u20131861","journal-title":"Blood"},{"key":"945_CR26","first-page":"847","volume":"148","author":"PL Nguyen","year":"1996","unstructured":"Nguyen PL, Harris NL, Ritz J, Robertson MJ (1996) Expression of CD95 antigen and BCL2 protein in non Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 148:847\u2013853","journal-title":"Am J Pathol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-0945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0945-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T10:01:36Z","timestamp":1591178496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-0945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-0945-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,30]]}}}